Skip to main content

Table 1 Patients 2006–2016 (n = 1535)a

From: Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Metastatic Melanoma (mM) 623 patients
 62% male, 38% female
 Median age, 53 years,
 Range, 19–84 years
Metastatic Renal Cell Cancer (mRCC) 919 patients
 72% male, 28% female
 Median age, 57 years,
 Range, 18–84 years
7 patients had both mM and mRCC – counted in each subset
Data retrospectively accrued 426 patients
Data prospectively accrued 1109 patients (72%)
Median follow-up 3.5+ years, range 1–8+ years
  1. a7 patients had both diseases